Research ExplorerPublicationsAdditional androgen deprivation makes the difference: Bioche...

Additional androgen deprivation makes the difference: Biochemical recurrence-free survival in prostate cancer patients after HDR brachytherapy and external beam radiotherapy

Standard

Additional androgen deprivation makes the difference: Biochemical recurrence-free survival in prostate cancer patients after HDR brachytherapy and external beam radiotherapy. / Schiffmann, Jonas; Lesmana, Hans; Tennstedt, Pierre; Beyer, Burkhard; Boehm, Katharina; Platz, Volker; Tilki, Derya; Salomon, Georg; Petersen, Cordula; Krüll, Andreas; Graefen, Markus; Schwarz, Rudolf.

In: STRAHLENTHER ONKOL, Vol. 191, No. 4, 01.04.2015, p. 330-337.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Schiffmann, J, Lesmana, H, Tennstedt, P, Beyer, B, Boehm, K, Platz, V, Tilki, D, Salomon, G, Petersen, C, Krüll, A, Graefen, M & Schwarz, R 2015, 'Additional androgen deprivation makes the difference: Biochemical recurrence-free survival in prostate cancer patients after HDR brachytherapy and external beam radiotherapy', STRAHLENTHER ONKOL, vol. 191, no. 4, pp. 330-337. https://doi.org/10.1007/s00066-014-0794-y

APA

Schiffmann, J., Lesmana, H., Tennstedt, P., Beyer, B., Boehm, K., Platz, V., Tilki, D., Salomon, G., Petersen, C., Krüll, A., Graefen, M., & Schwarz, R. (2015). Additional androgen deprivation makes the difference: Biochemical recurrence-free survival in prostate cancer patients after HDR brachytherapy and external beam radiotherapy. STRAHLENTHER ONKOL, 191(4), 330-337. https://doi.org/10.1007/s00066-014-0794-y

Vancouver

Schiffmann J, Lesmana H, Tennstedt P, Beyer B, Boehm K, Platz V et al. Additional androgen deprivation makes the difference: Biochemical recurrence-free survival in prostate cancer patients after HDR brachytherapy and external beam radiotherapy. STRAHLENTHER ONKOL. 2015 Apr 1;191(4):330-337. https://doi.org/10.1007/s00066-014-0794-y

Bibtex

@article{27af58c542b74e738117f668e3429d19,
title = "Additional androgen deprivation makes the difference: Biochemical recurrence-free survival in prostate cancer patients after HDR brachytherapy and external beam radiotherapy",
abstract = "BACKGROUND: The role of additional androgen deprivation therapy (ADT) in prostate cancer (PCa) patients treated with combined HDR brachytherapy (HDR-BT) and external beam radiotherapy (EBRT) is still unknown.PATIENTS AND METHODS: Consecutive PCa patients classified as D'Amico intermediate and high-risk who underwent HDR-BT and EBRT treatment ± ADT at our institution between January 1999 and February 2009 were assessed. Multivariable Cox regression models predicting biochemical recurrence (BCR) were performed. BCR-free survival was assessed with Kaplan-Meier analyses.RESULTS: Overall, 392 patients were assessable. Of these, 221 (56.4 %) underwent trimodality (HDR-BT and EBRT and ADT) and 171 (43.6 %) bimodality (HDR-BT and EBRT) treatment. Additional ADT administration reduced the risk of BCR (HR: 0.4, 95 % CI: 0.3-0.7, p < 0.001). D'Amico high-risk patients had superior BCR-free survival when additional ADT was administered (log-rank p < 0.001). No significant difference for BCR-free survival was recorded when additional ADT was administered to D'Amico intermediate-risk patients (log-rank p = 0.2).CONCLUSIONS: Additional ADT administration improves biochemical control in D'Amico high-risk patients when HDR-BT and EBRT are combined. Physicians should consider the oncological benefit of ADT administration for these patients during the decision-making process.",
author = "Jonas Schiffmann and Hans Lesmana and Pierre Tennstedt and Burkhard Beyer and Katharina Boehm and Volker Platz and Derya Tilki and Georg Salomon and Cordula Petersen and Andreas Kr{\"u}ll and Markus Graefen and Rudolf Schwarz",
year = "2015",
month = apr,
day = "1",
doi = "10.1007/s00066-014-0794-y",
language = "English",
volume = "191",
pages = "330--337",
journal = "STRAHLENTHER ONKOL",
issn = "0179-7158",
publisher = "Urban und Vogel",
number = "4",

}

RIS

TY - JOUR

T1 - Additional androgen deprivation makes the difference: Biochemical recurrence-free survival in prostate cancer patients after HDR brachytherapy and external beam radiotherapy

AU - Schiffmann, Jonas

AU - Lesmana, Hans

AU - Tennstedt, Pierre

AU - Beyer, Burkhard

AU - Boehm, Katharina

AU - Platz, Volker

AU - Tilki, Derya

AU - Salomon, Georg

AU - Petersen, Cordula

AU - Krüll, Andreas

AU - Graefen, Markus

AU - Schwarz, Rudolf

PY - 2015/4/1

Y1 - 2015/4/1

N2 - BACKGROUND: The role of additional androgen deprivation therapy (ADT) in prostate cancer (PCa) patients treated with combined HDR brachytherapy (HDR-BT) and external beam radiotherapy (EBRT) is still unknown.PATIENTS AND METHODS: Consecutive PCa patients classified as D'Amico intermediate and high-risk who underwent HDR-BT and EBRT treatment ± ADT at our institution between January 1999 and February 2009 were assessed. Multivariable Cox regression models predicting biochemical recurrence (BCR) were performed. BCR-free survival was assessed with Kaplan-Meier analyses.RESULTS: Overall, 392 patients were assessable. Of these, 221 (56.4 %) underwent trimodality (HDR-BT and EBRT and ADT) and 171 (43.6 %) bimodality (HDR-BT and EBRT) treatment. Additional ADT administration reduced the risk of BCR (HR: 0.4, 95 % CI: 0.3-0.7, p < 0.001). D'Amico high-risk patients had superior BCR-free survival when additional ADT was administered (log-rank p < 0.001). No significant difference for BCR-free survival was recorded when additional ADT was administered to D'Amico intermediate-risk patients (log-rank p = 0.2).CONCLUSIONS: Additional ADT administration improves biochemical control in D'Amico high-risk patients when HDR-BT and EBRT are combined. Physicians should consider the oncological benefit of ADT administration for these patients during the decision-making process.

AB - BACKGROUND: The role of additional androgen deprivation therapy (ADT) in prostate cancer (PCa) patients treated with combined HDR brachytherapy (HDR-BT) and external beam radiotherapy (EBRT) is still unknown.PATIENTS AND METHODS: Consecutive PCa patients classified as D'Amico intermediate and high-risk who underwent HDR-BT and EBRT treatment ± ADT at our institution between January 1999 and February 2009 were assessed. Multivariable Cox regression models predicting biochemical recurrence (BCR) were performed. BCR-free survival was assessed with Kaplan-Meier analyses.RESULTS: Overall, 392 patients were assessable. Of these, 221 (56.4 %) underwent trimodality (HDR-BT and EBRT and ADT) and 171 (43.6 %) bimodality (HDR-BT and EBRT) treatment. Additional ADT administration reduced the risk of BCR (HR: 0.4, 95 % CI: 0.3-0.7, p < 0.001). D'Amico high-risk patients had superior BCR-free survival when additional ADT was administered (log-rank p < 0.001). No significant difference for BCR-free survival was recorded when additional ADT was administered to D'Amico intermediate-risk patients (log-rank p = 0.2).CONCLUSIONS: Additional ADT administration improves biochemical control in D'Amico high-risk patients when HDR-BT and EBRT are combined. Physicians should consider the oncological benefit of ADT administration for these patients during the decision-making process.

U2 - 10.1007/s00066-014-0794-y

DO - 10.1007/s00066-014-0794-y

M3 - SCORING: Journal article

C2 - 25471276

VL - 191

SP - 330

EP - 337

JO - STRAHLENTHER ONKOL

JF - STRAHLENTHER ONKOL

SN - 0179-7158

IS - 4

ER -